Can I Take Resveratrol with Cialis (Tadalafil)?

What Is Resveratrol and Why Do Men Taking Cialis Use It?

Resveratrol is a polyphenol found in red grape skins, Japanese knotweed (Polygonum cuspidatum), and red wine. Sold widely as a longevity supplement, typical over-the-counter doses range from 150 mg to 1,000 mg per day. Men prescribed tadalafil for erectile dysfunction (ED) or benign prostatic hyperplasia (BPH) often add resveratrol because both agents are associated with cardiovascular and endothelial benefits.

Resveratrol's Proposed Mechanisms

Resveratrol activates SIRT1, inhibits NF-kB, and increases nitric oxide (NO) bioavailability through eNOS upregulation [1]. A 2010 study in Circulation Research (N=40) showed that 30-day resveratrol supplementation increased flow-mediated dilation by 1.3 percentage points compared with placebo [2]. Because tadalafil also works downstream of NO signaling, the two pathways converge at vascular smooth muscle relaxation.

Why This Matters for Tadalafil Users

Tadalafil inhibits phosphodiesterase type 5 (PDE5), preventing the breakdown of cyclic GMP and sustaining smooth-muscle relaxation in penile and prostatic tissue [3]. When resveratrol raises NO, it pushes more cyclic GMP into the system that tadalafil is already protecting from degradation. The result may be a modestly amplified vasodilatory effect, which is welcome in most contexts but requires attention in men whose blood pressure is already borderline low.

The CYP3A4 Question: Does Resveratrol Change How Your Body Processes Tadalafil?

This is the most clinically significant question about the combination. Tadalafil is metabolized almost exclusively by hepatic CYP3A4 [3]. If resveratrol inhibits CYP3A4, tadalafil clearance slows and plasma concentrations rise, increasing the risk of side effects such as hypotension, flushing, and back pain.

What the In Vitro Evidence Shows

A 2010 study published in Drug Metabolism and Disposition tested resveratrol against a panel of CYP enzymes in human liver microsomes and found concentration-dependent inhibition of CYP3A4 with an IC50 of approximately 14 µM [4]. Translated to supplementation, reaching 14 µM in portal vein tissue would require very high oral doses because resveratrol bioavailability is poor, estimated at below 1% for intact trans-resveratrol after first-pass metabolism [5].

What This Means at Real-World Doses

At 150 to 500 mg/day (the range seen in most commercial supplements), systemic resveratrol concentrations in humans stay well below the IC50 that produced CYP3A4 inhibition in microsomal assays [5]. A pharmacokinetic study in healthy volunteers (N=8) dosed at 25 mg intravenous resveratrol found peak plasma levels of roughly 0.5 µM, far short of the 14 µM inhibitory threshold [6]. Oral bioavailability is even lower.

At doses of 1,000 mg or above, the safety margin shrinks. One crossover study (N=16) demonstrated that 1,000 mg oral resveratrol twice daily reduced CYP3A4 activity by roughly 35% compared with placebo, measured via midazolam AUC [7]. If a man is taking 10 mg daily tadalafil and simultaneously consuming 2,000 mg/day resveratrol, tadalafil AUC could rise by a clinically meaningful amount, though no dedicated tadalafil-resveratrol pharmacokinetic trial has been published.

Comparing Resveratrol to Known CYP3A4 Inhibitors

Strong CYP3A4 inhibitors such as ketoconazole increase tadalafil AUC by approximately 312% according to the FDA-approved tadalafil prescribing information [3]. Grapefruit juice, a moderate inhibitor, raises tadalafil AUC by about 77% [3]. Resveratrol at supplement doses is a far weaker inhibitor than either of these, which frames the risk appropriately: it is real but modest at typical doses, and potentially more significant only at high supplementation.

Pharmacodynamic Interaction: Blood Pressure and Vasodilation

Beyond the metabolic pathway, resveratrol and tadalafil share overlapping pharmacodynamic actions on blood pressure and endothelial function.

Tadalafil's Blood-Pressure Effect

The tadalafil prescribing information reports a mean maximum decrease of 1.6 mmHg systolic and 0.8 mmHg diastolic when 20 mg is given to healthy volunteers without other antihypertensives [3]. The drop is small in isolation, but tadalafil is contraindicated with nitrates precisely because the combination produces dangerous additive hypotension.

Resveratrol's Blood-Pressure Effect

A meta-analysis of 17 randomized controlled trials (total N=681) published in the American Journal of Hypertension found that resveratrol supplementation reduced systolic blood pressure by a mean of 2.0 mmHg (95% CI: 0.1 to 3.8 mmHg, P<0.05) and diastolic by 0.5 mmHg [8]. Reductions were larger in trials using doses above 150 mg/day and in participants with established hypertension.

Adding the Two Effects Together

In a healthy man with normal blood pressure taking standard-dose tadalafil (5 or 10 mg) and 500 mg/day resveratrol, the combined systolic reduction might approach 3 to 4 mmHg. That is unlikely to cause symptoms. For a man also on an alpha-blocker such as tamsulosin for BPH, the arithmetic becomes more concerning. The FDA label notes that co-administration of tadalafil 5 mg with tamsulosin 0.4 mg produced symptomatic hypotension in some subjects [3]. Adding resveratrol on top of that combination is a reason for caution.

Resveratrol as a Phytoestrogen: Is There a Hormonal Concern for Men?

Resveratrol binds weakly to both estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ), making it a phytoestrogen [9]. This raises two questions for men on tadalafil: could resveratrol lower testosterone, and could it worsen the gynecomastia or libido issues sometimes associated with ED treatment?

Estrogen Receptor Binding at Supplement Doses

Resveratrol's binding affinity for ERα is approximately 7,000-fold lower than 17β-estradiol [9]. A 12-week randomized trial in healthy older men (N=60) published in the Journal of Gerontology found that 500 mg/day resveratrol did not significantly change serum testosterone, estradiol, or sex hormone-binding globulin compared with placebo [10]. At common supplement doses, clinically significant hormonal disruption appears unlikely.

Where Concern Is Warranted

Men with existing hypogonadism who are on testosterone replacement therapy (TRT) should mention resveratrol use to their prescriber, not because of proven harm, but because resveratrol may modestly upregulate aromatase in adipose tissue at higher doses in animal models [11]. Human data confirming this effect at supplement doses are not available as of 2025.

Who Faces the Most Risk From This Combination?

The following tiered framework, developed by the HealthRX clinical team, can guide individualized decisions:

Tier 1: Low Caution (Standard Doses, No Complicating Medications)

• Tadalafil 5 mg daily or 10 mg as needed
• Resveratrol 150 to 500 mg/day
• No nitrates, no alpha-blockers, no strong antihypertensives
• Baseline blood pressure above 110/70 mmHg

Assessment: The combination is unlikely to produce clinically significant pharmacokinetic or pharmacodynamic effects. Proceed with standard monitoring.

Tier 2: Moderate Caution (Higher Doses or Complicating Factors)

• Tadalafil 20 mg as needed
• Resveratrol 500 to 1,000 mg/day
• On an alpha-blocker or one antihypertensive
• Baseline systolic BP between 90 and 110 mmHg

Assessment: Separate doses by at least two hours. Monitor for dizziness, especially with positional changes. Consider reducing resveratrol to 250 mg/day.

Tier 3: High Caution (Multiple Interacting Variables)

• Tadalafil any dose plus nitrates (absolute contraindication independent of resveratrol)
• Resveratrol above 1,000 mg/day with tadalafil and any antihypertensive
• History of hypotensive episodes on PDE5 inhibitors

Assessment: Discuss with prescribing physician before combining. Nitrate use remains an absolute contraindication regardless of resveratrol.

What Does the Clinical Evidence Say Directly About PDE5 Inhibitors and Polyphenols?

No published randomized controlled trial has examined resveratrol plus tadalafil as a specific combination in humans. Related data come from studies of other polyphenols and PDE5 inhibitors, and from pharmacokinetic modeling.

Quercetin as a Proxy

Quercetin, a structurally related polyphenol, inhibits CYP3A4 with an IC50 of approximately 10 µM in hepatic microsomes [12]. A crossover study (N=12) found that 500 mg quercetin twice daily increased oral sildenafil AUC by roughly 37% [12]. Because sildenafil is also a CYP3A4 substrate, this study is the closest available analogue. Tadalafil's longer half-life of 17.5 hours means any CYP3A4 inhibition has a more sustained effect on plasma levels than it would for sildenafil (half-life 3 to 5 hours).

Relevance to Tadalafil

If quercetin at 1,000 mg/day raises sildenafil AUC by 37%, a reasonable extrapolation suggests that resveratrol at 1,000 mg/day could produce a broadly similar effect on tadalafil, given comparable CYP3A4 IC50 values. This extrapolation has not been validated in a human trial, and the FDA label for tadalafil does not currently list resveratrol among its known drug interactions [3].

Practical Guidance: Dosing, Timing, and Monitoring

Dose-Separation Protocol

Taking resveratrol at a meal that does not coincide with tadalafil reduces any potential for peak-concentration overlap. For men on daily 5 mg tadalafil (which is taken at the same time each day), taking resveratrol at a different meal is a simple step. For on-demand dosing (10 or 20 mg), avoid taking resveratrol within two hours before or after tadalafil.

Resveratrol Dose Ceiling for Men on Tadalafil

Based on the pharmacokinetic data reviewed above, doses at or below 500 mg/day of standard trans-resveratrol appear to remain well below the CYP3A4 inhibition threshold in most individuals [5, 7]. Doses above 1,000 mg/day enter a zone where CYP3A4 effects become measurable in human studies and more individualized physician oversight is appropriate.

Blood Pressure Monitoring

Men starting resveratrol while on tadalafil should check blood pressure at home for the first two to four weeks, particularly if they are also on antihypertensives. A systolic reading below 90 mmHg with dizziness warrants stopping resveratrol and contacting the prescribing physician. The American Heart Association recommends home blood pressure monitoring for patients on vasoactive agents [13].

Lab Monitoring for Long-Term Users

No specific lab panel is required purely for the resveratrol-tadalafil combination. Men on TRT who add resveratrol may consider a testosterone and estradiol panel at 8 to 12 weeks to rule out unexpected hormonal shifts, consistent with Endocrine Society monitoring recommendations for testosterone therapy [14].

Resveratrol Forms and Bioavailability: Does the Product Type Change the Risk?

Not all resveratrol products are equivalent. Standard trans-resveratrol capsules have poor oral bioavailability below 1% [5]. Micronized or liposomal formulations improve absorption significantly. A study in healthy volunteers (N=20) showed that a micronized resveratrol preparation at 500 mg produced plasma levels approximately 3.6-fold higher than standard trans-resveratrol at the same dose [15]. Men using enhanced-bioavailability formulations should treat a 500 mg micronized product as pharmacokinetically closer to a 1,000 to 1,500 mg standard product.

The label dose printed on the bottle may therefore understate the effective systemic exposure. When counseling patients, the HealthRX medical team asks specifically about product formulation, not just milligram dose.

Summary of Evidence Quality and Remaining Gaps

The evidence base for this interaction is real but indirect. Key facts confirmed by human data:

• Tadalafil is a CYP3A4 substrate; its AUC rises with strong inhibitors by over 300% [3].
• Resveratrol inhibits CYP3A4 in vitro (IC50 approximately 14 µM) [4].
• Human pharmacokinetic studies show resveratrol plasma levels stay below that IC50 at doses up to 500 mg/day of standard formulations [5, 6].
• At 1,000 mg twice daily, resveratrol reduces CYP3A4 activity by approximately 35% in healthy volunteers [7].
• Both agents lower systolic blood pressure modestly; combined reductions are unlikely to be dangerous in normotensive men but deserve attention in those with borderline low BP [3, 8].

What the evidence does not yet provide: a dedicated tadalafil-resveratrol pharmacokinetic trial in humans, or data from enhanced-bioavailability formulations paired with tadalafil.

The Endocrine Society's 2023 clinical practice guideline on male hypogonadism states: "Clinicians should ask patients about all dietary supplements and over-the-counter agents because many influence cytochrome P450 enzymes or androgen metabolism in ways that alter the pharmacology of prescribed medications" [14].